masthead-news

News & Events

HTG Molecular Diagnostics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

TUCSON, Ariz. , Jan. 23, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced the completion of its previously announced underwritten public offering of 13,915,000 shares…

Read More

Posted on:
 

2018 Molecular Pathology in Oncology

Join HTG at the Molecular Pathology in Oncology at stand 7 and learn more about our HTG EdgeSeq PATH Assay. The assay has been designed for retrospective gene expression profiling to complement traditional immunohistochemistry testing by allowing investigators to assess mRNA expression of large numbers of markers when tissue availability is limited.

Biomedical Research Centre | The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research | London, UK | March 15, 2018

Read More

Posted on:
 

HTG Molecular Diagnostics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Tuesday, November 7

TUCSON, Ariz., Oct. 20, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it will report its financial results for the three and nine months ended September 30, 2017 after the market close on Tuesday, November 7th. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

Read More

Posted on:

Page last updated March 20, 2023